Sigve Andersen1, Ørjan Solstad2, Line Moi3, Tom Donnem4, Marte Eilertsen5, Yngve Nordby6, Nora Ness7, Elin Richardsen3, Lill-Tove Busund3, Roy M Bremnes4. 1. Department of Clinical Medicine, Translational Cancer Research Group, The Arctic University of Norway, Tromso, Norway; Department of Oncology, University Hospital of North Norway, Tromso. Electronic address: sigve.andersen@uit.no. 2. Department of Pathology, University Hospital of North Norway, Tromso, Norway. 3. Department of Pathology, University Hospital of North Norway, Tromso, Norway; Department of Medical Biology, Translational Cancer Research Group, The Arctic University of Norway, Tromso, Norway. 4. Department of Clinical Medicine, Translational Cancer Research Group, The Arctic University of Norway, Tromso, Norway; Department of Oncology, University Hospital of North Norway, Tromso. 5. Department of Clinical Medicine, Translational Cancer Research Group, The Arctic University of Norway, Tromso, Norway. 6. Department of Clinical Medicine, Translational Cancer Research Group, The Arctic University of Norway, Tromso, Norway; Department of Urology, University Hospital of North Norway, Tromso, Norway. 7. Department of Medical Biology, Translational Cancer Research Group, The Arctic University of Norway, Tromso, Norway.
Abstract
BACKGROUND: Lactate import or export over cell membranes is facilitated by monocarboxylate transporters (MCTs) 1 and 4. Expression profiles can be markers of an oxidative or glycolytic phenotype. Descriptive studies and functional studies in neoplastic cells and fibroblasts in prostate cancer (PC) have suggested a distinct phenotype. We aimed to explore expression of MCT1 and MCT4 in PC cells and surrounding stroma in a large cohort. Additionally, we wanted to find out if distinct expression profiles were associated with biochemical failure-free survival (BFFS). METHODS: Tissue microarrays were constructed from 535 patients with radical prostatectomies between January 1, 1995, and December 31, 2005. Immunohistochemistry was used to detect expression, and degrees of expression were evaluated semiquantitatively by 2 pathologists using light microscopy. RESULTS: For MCT1, there was only epithelial expression, whereas there was a low level of expression of MCT4 in tumor and stroma. A total of 172 patients had a low expression of MCT1 in tumor and MCT4 in stroma. There were 232 patients who had a high expression of MCT1 and a low expression of MCT4 in stroma. Only 11 patients had a low tumoral MCT1 expression and a high stromal MCT4 expression, and 26 patients (5%) had a high expression of both. Patients with a high-high combination had a significantly reduced BFFS (P = 0.011), and when adjusting for other factors, its effect was significant and independent (HR = 1.99, CI 95%: 1.09-3.62; P = 0.024). CONCLUSIONS: This study adds to the current understanding of the reversed Warburg effect to be a significant phenotype in PC. High coexpression of MCT1 in tumor and MCT4 in stroma is independently associated to a worse BFFS, and the strength of this association is as strong as having a Gleason score of ≥9.
BACKGROUND:Lactate import or export over cell membranes is facilitated by monocarboxylate transporters (MCTs) 1 and 4. Expression profiles can be markers of an oxidative or glycolytic phenotype. Descriptive studies and functional studies in neoplastic cells and fibroblasts in prostate cancer (PC) have suggested a distinct phenotype. We aimed to explore expression of MCT1 and MCT4 in PC cells and surrounding stroma in a large cohort. Additionally, we wanted to find out if distinct expression profiles were associated with biochemical failure-free survival (BFFS). METHODS: Tissue microarrays were constructed from 535 patients with radical prostatectomies between January 1, 1995, and December 31, 2005. Immunohistochemistry was used to detect expression, and degrees of expression were evaluated semiquantitatively by 2 pathologists using light microscopy. RESULTS: For MCT1, there was only epithelial expression, whereas there was a low level of expression of MCT4 in tumor and stroma. A total of 172 patients had a low expression of MCT1 in tumor and MCT4 in stroma. There were 232 patients who had a high expression of MCT1 and a low expression of MCT4 in stroma. Only 11 patients had a low tumoralMCT1 expression and a high stromal MCT4 expression, and 26 patients (5%) had a high expression of both. Patients with a high-high combination had a significantly reduced BFFS (P = 0.011), and when adjusting for other factors, its effect was significant and independent (HR = 1.99, CI 95%: 1.09-3.62; P = 0.024). CONCLUSIONS: This study adds to the current understanding of the reversed Warburg effect to be a significant phenotype in PC. High coexpression of MCT1 in tumor and MCT4 in stroma is independently associated to a worse BFFS, and the strength of this association is as strong as having a Gleason score of ≥9.
Authors: Jie Wu; Yun Hong; Tong Wu; Juan Wang; Xiaobing Chen; Zhi Wang; Bin Cheng; Juan Xia Journal: Int J Mol Med Date: 2017-11-17 Impact factor: 4.101
Authors: Heikki Huhta; Olli Helminen; Sami Palomäki; Joonas H Kauppila; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen Journal: Oncotarget Date: 2017-04-04
Authors: Annie Rochette; Nadia Boufaied; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Hayley C Whitaker; Antonio Ramos-Montoya; David E Neal; Alice Dragomir; Armen Aprikian; Simone Chevalier; Axel A Thomson Journal: Br J Cancer Date: 2017-02-02 Impact factor: 7.640
Authors: Tristan Barrett; Ferdia A Gallagher; Nikita Sushentsev; Mary A McLean; Anne Y Warren; Arnold J V Benjamin; Cara Brodie; Amy Frary; Andrew B Gill; Julia Jones; Joshua D Kaggie; Benjamin W Lamb; Matthew J Locke; Jodi L Miller; Ian G Mills; Andrew N Priest; Fraser J L Robb; Nimish Shah; Rolf F Schulte; Martin J Graves; Vincent J Gnanapragasam; Kevin M Brindle Journal: Nat Commun Date: 2022-01-24 Impact factor: 14.919
Authors: Cory D Bovenzi; James Hamilton; Patrick Tassone; Jennifer Johnson; David M Cognetti; Adam Luginbuhl; William M Keane; Tingting Zhan; Madalina Tuluc; Voichita Bar-Ad; Ubaldo Martinez-Outschoorn; Joseph M Curry Journal: Biomed Res Int Date: 2015-12-08 Impact factor: 3.411